The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: The SPICE trial

Abstract

In this randomised, double-blind, placebo-controlled multicenter study, adults with NYHA class II or III CHF and reduced left ventricular ejection fraction (LVEF menší nebo rovno 35%) were included and received 900 mg/day WS 1442 or placebo for 24 months. Primary endpoint was time until first cardiac event.